Add to Calendar2019-09-20 08:00:002019-09-21 11:15:00Emerging Topic Conference: The Genomics Revolution
The conference will focus on genomics and the changing approach to diagnostics, management and research in adult and pediatric liver diseases.
Arlington, VA 22202
Add to Calendar2019-10-04 08:00:002019-10-05 14:00:00AASLD / EASL ALD Conference
This meeting will bridge critical gaps in ALD diagnosis, management and clinical trial design.
1 W. Wacker Drive
Chicago, IL 60601
Add to Calendar2019-11-08 09:00:002019-11-12 14:00:00The Liver Meeting
The Liver MeetingÂ® is the annual must-attend event bringing together 9,500 attendees from around the world to exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.
Add to Calendar2019-12-14 08:00:002019-12-15 17:00:00TASL-AASLD Joint Symposium: HBV Elimination
Doctors Anna S. Lok and K. Rajender Reddy will join Dr. Jia-Horng Kao and other faculty from Taiwan to host the first TASL-AASLD Joint Symposium as part of the TASL (Taiwan Association for the Study of the Liver) Annual Meeting, December 14-15, 2019 in Taipei.
Beitou District, Taipei City
Add to Calendar2020-03-20 08:00:002020-03-21 15:00:00Emerging Topic Conference: Nuclear Receptors as Common Clinical Targets for the Treatment of Cholestatic and Nonalcoholic Fatty Liver Diseases
More information is coming soon.
LiverLearningÂ® is the official eLearning portal of AASLD. Users can access educational resources by topic, speaker, event, and content type â€” including video, audio, and slide decks. Continuing education (CME/CE credits and MOC points) is available for a variety of enduring materials on the portal. All current AASLD members automatically receive complete access to LiverLearningÂ®, and non-members can purchase access for one year with a subscription.
Medical oversight for ongoing clinical trials throughout conduct and support all medical and scientific aspects of clinical trial(s).
Contribute to the strategic planning, authoring, and review of clinical and regulatory documents.
Provide medical expertise and support to externally facing groups/stakeholders, including the field medical team, medical information and the commercial organization.
Maintain close collaboration and cooperation with Clinical Operations on the implementation and execution of clinical studies.
Contribute to the strategic planning and execution of clinical development plans.
MD degree with at least 5 years of direct biotechnology or pharmaceutical industry experience in Clinical Research.
Prior experience in Hepatology, Gastroenterology, Metabolic Diseases, or related field, preferred.
Knowledge of GCPs, ICH guidelines and FDA regulations and familiarity with EMA/CHMP regulations and guidelines, and other international regulatory requirements.
Ability to effectively present ideas and document complex medical/clinical concepts in both written and oral communication.
Strong interpersonal and communication skills; proactive approach. Able to work both independently and in a team environment.
Detail-oriented, with good organizational, prioritization, and time management proficiencies. Must be able to work on multiple projects simultaneously.
Internal Number: 001
About Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.
Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH). In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).
Viking’s other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in pat...ients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo. Other programs also include VK0612, a first-in-class, orally available drug candidate in Phase 2 development for the treatment of type 2 diabetes as well as two earlier-stage programs targeting metabolic diseases and anemia. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.